CStone Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
CStone Pharmaceuticals's earnings have been declining at an average annual rate of -1.8%, while the Biotechs industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 35.9% per year.
Key information
-1.8%
Earnings growth rate
25.9%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 35.9% |
Return on equity | -124.3% |
Net Margin | -156.0% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How CStone Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 481 | -750 | 516 | 534 |
31 Mar 23 | 481 | -827 | 546 | 574 |
31 Dec 22 | 481 | -903 | 576 | 614 |
30 Sep 22 | 454 | -1,205 | 616 | 836 |
30 Jun 22 | 426 | -1,508 | 655 | 1,059 |
31 Mar 22 | 335 | -1,714 | 658 | 1,182 |
31 Dec 21 | 244 | -1,920 | 661 | 1,305 |
30 Sep 21 | 681 | -1,622 | 622 | 1,339 |
30 Jun 21 | 1,118 | -1,324 | 583 | 1,373 |
31 Mar 21 | 1,079 | -1,272 | 534 | 1,389 |
31 Dec 20 | 1,039 | -1,221 | 485 | 1,405 |
30 Sep 20 | 519 | -1,482 | 424 | 1,480 |
30 Jun 20 | -2 | -1,744 | 363 | 1,556 |
31 Mar 20 | -1 | -1,906 | 352 | 1,476 |
31 Dec 19 | 0 | -2,069 | 341 | 1,396 |
30 Sep 19 | 11 | -1,688 | 327 | 1,040 |
30 Jun 19 | 12 | -1,246 | 322 | 725 |
31 Mar 19 | 12 | -858 | 256 | 788 |
31 Dec 18 | 13 | -470 | 191 | 850 |
30 Sep 18 | 13 | -336 | 130 | 747 |
31 Dec 17 | 10 | -107 | 39 | 213 |
Quality Earnings: 2616 is currently unprofitable.
Growing Profit Margin: 2616 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2616 is unprofitable, and losses have increased over the past 5 years at a rate of 1.8% per year.
Accelerating Growth: Unable to compare 2616's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2616 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 2616 has a negative Return on Equity (-124.29%), as it is currently unprofitable.